newsfilter
← Earnings
Earnings Releases·

ALX Oncology — Third Quarter 2026 Earnings Summary

ALX Oncology reported a net loss of $21.8 million for the third quarter ended September 30, 2026, with cash, cash equivalents, and investments totaling $147.2 million sufficient to fund operations through the first half of 2028. The company announced the publication of Phase 2 ASPEN-06 trial data in Nature Medicine, which showed encouraging efficacy for evorpacept in HER2-positive gastric cancers, while enrollment for the Phase 2 ASPEN-09-Breast trial remains on track with topline data expected in the second half of 2027. Additionally, ALX Oncology plans to release safety and early efficacy data from the Phase 1 dose-escalation study of its EGFR-targeted ADC, ALX2004, in December 2026.

Company
ALX ONCOLOGY HOLDINGS INC
Sector
Healthcare
Industry
Biotechnology